Search
Boceprevir
go.drugbank.com/drugs/DB08873ApprovedWithdrawnVictrelis is no longer widely used as interferon-free therapies have been developed. … Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).
Pyridostigmine
go.drugbank.com/drugs/DB00545ApprovedInvestigationalBy inhibiting the breakdown of acetylcholine in the neuromuscular junction, they increase signalling and relieve symptoms. … [L32408, L32413] In addition to treating myasthenia gravis, pyridostigmine is used to reverse neuromuscular blocks, relieve symptoms in congenital myasthenic syndromes, and protect against certain nerve
International brands: Kalymin NHomatropine
go.drugbank.com/drugs/DB11181Approveduse has not been approved by the FDA to be safe and effective. … Homatropine hydrobromide has been administered as ophthalmic solutions as a cycloplegic to temporarily paralyze accomodation, and to induce mydriasis (the dilation of the pupil); however such therapeutic
Caspofungin
go.drugbank.com/drugs/DB00520ApprovedInvestigationalCaspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. … It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall.
Synonyms: (4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-transCatumaxomab
go.drugbank.com/drugs/DB06607ApprovedWithdrawnCatumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites [L1122]. … Its market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency.
Finafloxacin
go.drugbank.com/drugs/DB09047ApprovedWithdrawnFinafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014. … Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.
Eugenol
go.drugbank.com/drugs/DB09086ApprovedInvestigationalEugenol is a naturally occurring phenolic molecule found in several plants such as cinnamon, clove, and bay leaves. … Although not currently available in any FDA-approved products (including OTC), eugenol has been found to have anti-inflammatory, neuroprotective, antipyretic, antioxidant, antifungal and analgesic properties
Trimebutine
go.drugbank.com/drugs/DB09089ApprovedInvestigationalTrimebutine is not a FDA-approved drug, but it is available in Canada and several other international countries. … It is used to restore normal bowel function and is commonly present in pharmaceutical mixtures as trimebutine maleate salt form.
International brands: Ni Wei Fu, Procinet NFAntihemophilic factor (recombinant), PEGylated
go.drugbank.com/drugs/DB09329ApprovedInvestigationalAntihemophilic Factor (Recombinant), PEGylated, was approved by the FDA in December 2016 as the product _Adynovate_ [FDA label]. … PEGylation is the covalent attachment of a polyethylene glycol polymer, called PEG, to a drug or protein.
Tezacaftor
go.drugbank.com/drugs/DB11712ApprovedInvestigational[L1595] It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to manage cystic fibrosis.[L6814] This drug was approved by the FDA on February 12, 2018. … [L4894] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion